Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Mavacamten, a first-in-class cardiac myosin inhibitor, reduces symptoms and improves health status in patients with obstructive hypertrophic cardiomyopathy, according to findings from the EXPLORER-HCM trial.
Anti-inflammatory therapy with low-dose colchicine reduces the risk of cardiovascular events by 31% compared with placebo in patients with chronic coronary artery disease, according to findings from the LoDoCo2 trial presented at the ESC Congress 2020.
A strategy of early rhythm control for patients with recently diagnosed atrial fibrillation reduces the risk of cardiovascular events compared with usual care, according to findings from the EAST-AFNET 4 trial.
Empagliflozin, an SGLT2 inhibitor, reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with reduced ejection fraction with or without diabetes mellitus, according to findings from the EMPEROR-Reduced trial.
Findings from the ATPCI trial show that trimetazidine is safe but not protective against angina and cardiac events in the long term after percutaneous coronary intervention.
According to findings from the POPular TAVI trial, in patients without an indication for oral anticoagulation, the use of aspirin alone compared with aspirin plus clopidogrel after transcatheter aortic valve implantation significantly reduced bleeding rates and did not increase thromboembolic events.
A novel sequencing technique reveals ROS-induced position-specific oxidation of microRNAs provides a mechanism whereby elevated oxidative stress within the heart leads to hypertrophy.
Gene therapy with H19, a highly conserved long non-coding RNA H19, prevents and reverses pathological cardiac hypertrophy in animal models, according to a study by Thomas Thum and colleagues.
A new clinical trial in a dish study sheds light on a new mechanism that restores endothelial dysfunction with lovastatin in induced pluripotent stem cells that are derived from patients with dilated cardiomyopathy.
Visceral adipose tissue-resident macrophages can sense remote organ injury, such as myocardial infarction. In response, they undergo apoptosis, which can initiate de novo insulin resistance.
In atherosclerosis-prone mice, administration of small interfering RNA (siRNA)–nanoparticle system targeted to lesional macrophages to silence Camk2g improves plaque stability compared with control nanoparticles.
Myocardial infarction can accelerate tumour growth in a mouse model of breast cancer by promoting the reprogramming of myelopoietic progenitors to alter long-term immune responses that contribute to a protumoural environment.
In a prespecified secondary analysis of the ACCELERATE trial, Puri and colleagues report a stepwise relationship between lipoprotein(a) levels and risk of major adverse cardiac events in patients with high-sensitivity C-reactive protein levels ≥2 mg/l.
SS-31, an inhibitor of mitochondrial reactive oxygen species production, can rescue age-related cardiac dysfunction and normalize mitochondrial proton leak in old mice.
Type V collagen, a minor constituent of the myocardial scar that forms after ischaemic injury, is an important regulator of scar size via a previously unrecognized role in limiting integrin-dependent fibrosis.
Maternal exercise during pregnancy confers benefits to offspring, including improvements in glucose metabolism, adiposity and cardiac function, via an oligosaccharide present in breast milk.
Non-coding de novo variants (DNVs) contribute to congenital heart disease (CHD) through transcriptional and post-transcriptional regulatory effects during cardiac development. The proportion of individuals with CHD ascribed to non-coding DNVs might be at least as high as that with CHD attributed to coding DNVs
A new study involving theoretical and experimental assays provides proof of concept of a fully biological self-restoring system that automatically detects and terminates cardiac arrhythmias.
In patients with COVID-19, myocardial injury is prevalent and is associated with an adverse prognosis and increased mortality, according to two retrospective cohort studies from China and the USA.
